Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Healing the Wounds of Diabetes

|Includes: Wound Management Technologies, Inc. (WNDM)

Healing the Wounds of Diabetes

 

In 2007 the Center for Disease Control (NASDAQ:CDC) released a study that estimated as many as 23.6 million people in the United States, or 7.8% of the US population, have been diagnosed with Diabetes.  According to the International Diabetes Federation, diabetes currently affects 246 million people worldwide and is expected to afflict over 380 million by 2025.  Many people are unaware of the severe pain and health issues surrounding the aging of diabetics and all of the factors that contribute to discomfort, amputation and/or death.  As reported by Gina Shaw, a reporter for WebMD, every 30 seconds, someone in the world loses a lower limb as a result of diabetes.  Furthermore, the fact that diabetes causes the formation of wounds, sores, and ulcers that are extremely painful and difficult to prevent and/or cure, makes this disease all the more virulent. For a person with diabetes, there's no such thing as a minor wound; even the smallest sore can turn into an ulcer that, if not properly treated, can lead to serious problems, including amputation. The amputation rate for people with diabetes is 10 times higher than for those without the disease. 

Per the Census, in the United States there is a proximately 2.58 members per household and approximately 303 million people in the US.  The statistics mean that less than 1 out of every 5 families are affected by diabetes, which is a stunning statistic.

The treatment of wounds and ulcers from diabetes is very complex. There have been many synthetic products or applications that have aided in mitigating the malevolent health issues associated with this disease.  Thus far, many of these products have caused health issues that proven to be more detrimental to the wellness of the individual than the health issues caused by diabetes itself.  The a few of the reason for this is that within these products are compounds that are often foreign to the body and are often synthetic in nature due to high costs and production issues. With the recent press on the potential concern over the Johnson & Johnson foot gel product, Regranex, there has been significant publicity detailing the potential risks associated with certain diabetic products due to the increased likelihood of developing cancer or even dying, according to U.S. health officials.

 

The majority of today’s current wound-care products lack the inclusion of a certain base derived from the protein Collagen, a substance that is ubiquitous throughout the human body.  With the correct combination of biological components, Collagen has been known to rapidly expedite the healing process of afflictions such as the wounds, sores and ulcers that are associated with diabetes.  

 

Wound Management Technologies, Inc. is one such company that has focused its efforts on combining Collagen with other components to create a product that aides in the healing process of diabetic afflictions.  Wound Management Technologies, Inc., through its subsidiary, Wound Care Innovations, LLC, distributes collagen-based wound-care products for pressure ulcers, diabetic ulcers, surgical wounds, ulcers due to arterial insufficiency, traumatic wounds, first and second degree burns, and superficial wounds. Its major product, CellerateRX®, is currently offered in both gel and powder forms.  The product is well known for its ability to significantly reduce the healing time of such complications, further reducing the risk of amputation, further infections or even more severe complications.

 

Wound Care Innovations, LLC recently announced an evidence-based study with a NE podiatric clinic evaluating the clinical performance of their advanced wound-care collagen product, CellerateRx, on diabetic venous ulcers. Venous stasis ulcers of the lower extremity are a common problem among diabetic patients and present significant quality-of-life issues, as well as tremendous costs to the healthcare system. It has been estimated that venous ulcers cause the loss of approximately 2 million working days per year and incur treatment costs of approximately $3 billion per year in the United States1. With the creation and distribution of this new product, Wound Care Innovation, LLC has the ability to have an enormously propitious effect on the diabetic community as well as the rest of ailing individuals everywhere.  "We have had very positive feedback from clinicians using CellerateRx® on these types of wounds. We look forward to providing this data to the medical community," stated Cathy Bradshaw, President of Wound Care Innovations.

 

 (1)     New England Journal of Medicine, Bergan et al